イスラエル - 英語 - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

イスラエル - 英語 - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

イスラエル - 英語 - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

イスラエル - 英語 - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

イスラエル - 英語 - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

イスラエル - 英語 - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

イスラエル - 英語 - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 1000 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

イスラエル - 英語 - Ministry of Health

medison pharma ltd - ataluren - granules for oral suspension - ataluren 250 mg - ataluren - translarna is indicated for the treatment of duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. efficacy has not been demonstrated in non-ambulatory patients. the presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ptc therapeutics ltd - ataluren - granules - 125mg

イギリス - 英語 - MHRA (Medicines & Healthcare Products Regulatory Agency)

ptc therapeutics ltd - ataluren - granules - 250mg